BACKGROUND: Studies of the effect of hormonal contraceptive use on the risk of HIV-1 acquisition have generated conflicting results. A recent study from Uganda and Zimbabwe found that women using hormonal contraception were at increased risk for HIV-1 if they were seronegative for herpes simplex virus type 2 (HSV-2), but not if they were HSV-2 seropositive. OBJECTIVE: To explore the effect of HSV-2 infection on the relationship between hormonal contraception and HIV-1 in a high-risk population. Hormonal contraception has previously been associated with increased HIV-1 risk in this population. METHODS: Data were from a prospective cohort study of 1206 HIV-1 seronegative sex workers from Mombasa, Kenya who were followed monthly. Multivariate Cox proportional hazards analyses were used to adjust for demographic and behavioral measures and incident sexually transmitted diseases. RESULTS: : Two hundred and thirty-three women acquired HIV-1 (8.7/100 person-years). HSV-2 prevalence (81%) and incidence (25.4/100 person-years) were high. In multivariate analysis, including adjustment for HSV-2, HIV-1 acquisition was associated with use of oral contraceptive pills [adjusted hazard ratio (HR), 1.46; 95% confidence interval (CI), 1.00-2.13] and depot medroxyprogesterone acetate (adjusted HR, 1.73; 95% CI, 1.28-2.34). The effect of contraception on HIV-1 susceptibility did not differ significantly between HSV-2 seronegative versus seropositive women. HSV-2 infection was associated with elevated HIV-1 risk (adjusted HR, 3.58; 95% CI, 1.64-7.82). CONCLUSIONS: In this group of high-risk African women, hormonal contraception and HSV-2 infection were both associated with increased risk for HIV-1 acquisition. HIV-1 risk associated with hormonal contraceptive use was not related to HSV-2 serostatus.
BACKGROUND: Studies of the effect of hormonal contraceptive use on the risk of HIV-1 acquisition have generated conflicting results. A recent study from Uganda and Zimbabwe found that women using hormonal contraception were at increased risk for HIV-1 if they were seronegative for herpes simplex virus type 2 (HSV-2), but not if they were HSV-2 seropositive. OBJECTIVE: To explore the effect of HSV-2 infection on the relationship between hormonal contraception and HIV-1 in a high-risk population. Hormonal contraception has previously been associated with increased HIV-1 risk in this population. METHODS: Data were from a prospective cohort study of 1206 HIV-1 seronegative sex workers from Mombasa, Kenya who were followed monthly. Multivariate Cox proportional hazards analyses were used to adjust for demographic and behavioral measures and incident sexually transmitted diseases. RESULTS: : Two hundred and thirty-three women acquired HIV-1 (8.7/100 person-years). HSV-2 prevalence (81%) and incidence (25.4/100 person-years) were high. In multivariate analysis, including adjustment for HSV-2, HIV-1 acquisition was associated with use of oral contraceptive pills [adjusted hazard ratio (HR), 1.46; 95% confidence interval (CI), 1.00-2.13] and depot medroxyprogesterone acetate (adjusted HR, 1.73; 95% CI, 1.28-2.34). The effect of contraception on HIV-1 susceptibility did not differ significantly between HSV-2 seronegative versus seropositive women. HSV-2 infection was associated with elevated HIV-1 risk (adjusted HR, 3.58; 95% CI, 1.64-7.82). CONCLUSIONS: In this group of high-risk African women, hormonal contraception and HSV-2 infection were both associated with increased risk for HIV-1 acquisition. HIV-1 risk associated with hormonal contraceptive use was not related to HSV-2 serostatus.
Authors: Alison C Roxby; David N Fredricks; Katherine Odem-Davis; Kristjana Ásbjörnsdóttir; Linnet Masese; Tina L Fiedler; Stephen De Rosa; Walter Jaoko; James N Kiarie; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Patricia L Bright; Abigail Norris Turner; Charles S Morrison; Emelita L Wong; Cynthia Kwok; Irina Yacobson; Rachel A Royce; Heidi O Tucker; Paul D Blumenthal Journal: Contraception Date: 2011-03-23 Impact factor: 3.375
Authors: Catherine A Chappell; Charles E Isaacs; Weimin Xu; Leslie A Meyn; Kevin Uranker; Charlene S Dezzutti; Bernard J Moncla; Sharon L Hillier Journal: Am J Obstet Gynecol Date: 2015-03-25 Impact factor: 8.661
Authors: Jennifer E Balkus; Elizabeth R Brown; Sharon L Hillier; Anne Coletti; Gita Ramjee; Nyaradzo Mgodi; Bonus Makanani; Cheri Reid; Francis Martinson; Lydia Soto-Torres; Salim S Abdool Karim; Zvavahera M Chirenje Journal: Contraception Date: 2015-10-28 Impact factor: 3.375
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Renee Heffron; Nelly Mugo; Edwin Were; James Kiarie; Elizabeth A Bukusi; Andrew Mujugira; Lisa M Frenkel; Deborah Donnell; Allan Ronald; Connie Celum; Jared M Baeten Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Stewart E Reid; James Y Dai; Jing Wang; Bupe N Sichalwe; Godspower Akpomiemie; Frances M Cowan; Sinead Delany-Moretlwe; Jared M Baeten; James P Hughes; Anna Wald; Connie Celum Journal: J Acquir Immune Defic Syndr Date: 2010-04 Impact factor: 3.731
Authors: Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo Journal: Lancet HIV Date: 2015-07 Impact factor: 12.767